Myostatin is a skeletal muscle target of growth hormone anabolic action.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To investigate the mechanisms of anabolic actions of GH on skeletal muscle growth, the researchers examined the in vitro and in vivo effects of GH on myostatin regulation.

Why It Was Studied

The inhibitory effect of GH on myostatin was sustained after 12 and 18 months of GH treatment.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Body Mass Index, Cells, Cultured, Gene Expression, Human Growth Hormone, In Vitro Techniques, Insulin-Like Growth Factor I and Mice.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2003 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.